PRESS RELEASE

Q1 2023 — Press release

Q1 2023PDF · 13 pages168 KB
P R E S S R E L E A S E
ELEVANCE HEALTH REPORTS FIRST QUARTER 2023 RESULTS
• First quarter GAAP net income was $8.30 per share, including net negative
adjustment items of $1.16 per share. Adjusted net income was $9.46* per share.
• Operating revenue grew 10.6% year-over-year to $41.9 billion
• Operating gain grew 16.6% year-over-year to $2.8 billion
• Medical enrollment increased 1.3 million members year-over-year to 48.1 million
members
• Second quarter 2023 dividend of $1.48 per share declared to shareholders
Indianapolis, Ind. - April 19, 2023 - Elevance Health, Inc. (NYSE: ELV) reported first quarter
2023 results reflecting strong financial performance, including double-digit growth in revenue,
operating earnings, and adjusted earnings per share.
“Elevance Health is off to a strong start in 2023, driven by our continued focus on whole health
and advancing health beyond healthcare,” said Gail K. Boudreaux, President and CEO. “Through
our diverse and expanding offering of products and solutions, and our alignment with high-
performing, value-based care providers, we continue to meet the needs of consumers, customers
and the communities we serve, advancing our strategy of becoming a lifetime, trusted health
partner.”
Given the strong start to the year and the momentum in each of our primary businesses, we now
expect GAAP net income to be greater than $29.50 per share in 2023, and adjusted net income to
be greater than $32.70 per share.
*Refer to GAAP reconciliation tables on page 12.
1

-- 1 of 13 --

CONSOLIDATED HIGHLIGHTS
Earnings Per Share: GAAP net income was $8.30 per share in the first quarter, including net negative
adjustment items of $1.16 per share. Adjusted net income was $9.46* per share.
*Please refer to the GAAP reconciliation tables on page 12.
Membership: Medical membership totaled approximately 48.1 million as of March 31, 2023, an
increase of 1.3 million, or 2.9 percent year-over-year, driven primarily by growth in Medicaid,
commercial fee-based, Medicare Advantage and ACA health plan members, partially offset by attrition
in our employer group risk-based business.
During the first quarter of 2023, medical membership increased by 593 thousand driven by organic
growth in Medicaid and commercial fee-based members.
Operating Revenue: Operating revenue was $41.9 billion in the first quarter of 2023, an increase of
$4.0 billion, or 10.6 percent year-over-year. The increase was primarily driven by higher premium
revenue due to membership growth in Medicaid and Medicare Advantage, as well as premium rate
increases in our Health Benefits business. The increase in operating revenue was further attributable to
growth in pharmacy product revenue within CarelonRx driven by growth in members served and script
volume.
Benefit Expense Ratio: The benefit expense ratio was 85.8 percent in the first quarter of 2023, a
decrease of 30 basis points year-over-year. The decrease was driven by our commercial risk-based
health plans.
Medical claims reserves established at December 31, 2022 developed in line with the Company’s
expectations as of the first quarter of 2023.
Days in Claims Payable: Days in Claims Payable was 46.0 days as of March 31, 2023, a decrease of
1.5 days from December 31, 2022 and a decrease of 0.9 days compared to March 31, 2022.
Operating Expense Ratio: The operating expense ratio was 11.5 percent in the first quarter of 2023,
unchanged from 11.5 percent in the first quarter of 2022.
Operating Cash Flow: Operating cash flow was approximately $6.5 billion, including the early receipt
of April's premium payments from CMS. Excluding that item, operating cash flow would have been
$3.5 billion, or 1.7 times net income in the first quarter of 2023, an increase of $963 million as compared
to the prior year quarter. The year-over-year increase was driven by favorable working capital changes
and growth in net income.
Share Repurchase Program: During the first quarter of 2023, the Company repurchased 1.3 million
shares of its common stock for $622 million, at a weighted average price of $476.66. As of March 31,
2023, the Company had approximately $6.3 billion of Board-approved share repurchase authorization
remaining.
Cash Dividend: During the first quarter of 2023, the Company paid a quarterly dividend of $1.48 per
share, representing a distribution of cash totaling $351 million.
On April 18, 2023, the Audit Committee of the Company's Board of Directors declared a second quarter
2023 dividend to shareholders of $1.48 per share. The second quarter dividend is payable on June 23,
2023, to shareholders of record at the close of business on June 9, 2023.
2

-- 2 of 13 --

Investment Portfolio & Capital Position: During the first quarter of 2023, the Company recorded net
losses of $113 million. During the first quarter of 2022, the Company recorded net losses of $151
million. These amounts are excluded from adjusted earnings per share.
As of March 31, 2023, the Company’s net unrealized loss position in the investment portfolio was $1.8
billion, consisting primarily of fixed maturity securities. As of March 31, 2023, cash and investments at
the parent company totaled approximately $1.1 billion.
3

-- 3 of 13 --

REPORTABLE SEGMENTS
Elevance Health has four reportable segments: Health Benefits, the aggregation of our Commercial & Specialty
Business and Government Business (comprised of Individual, Employer Group risk-based, Employer Group fee-based,
BlueCard businesses, Medicaid, Medicare, and Federal Health Products & Services businesses); CarelonRx (formerly
IngenioRx); Carelon Services (formerly known as Diversified Business Group); and Corporate & Other (comprised of
businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate
expenses not allocated to our other reportable segments).
Elevance Health, Inc.
Reportable Segment Highlights
(Unaudited)
(In millions) Three Months Ended March 31
2023 2022 Change
(Restated)
Operating Revenue
Health Benefits $37,280 $34,027 9.6 %
Carelon1 11,336 9,631 17.7 %
Corporate & Other 251 273 (8.1) %
Eliminations (6,969) (6,045) 15.3 %
Total Operating Revenue2 $41,898 $37,886 10.6 %
Operating Gain (Loss)
Health Benefits $2,159 $1,851 16.6 %
Carelon1 721 598 20.6 %
Corporate & Other (49) (22) NM3
Total Operating Gain2 $2,831 $2,427 16.6 %
Operating Margin
Health Benefits 5.8 % 5.4 % 40 bp
Carelon1 6.4 % 6.2 % 20 bp
Total Operating Margin2 6.8 % 6.4 % 40 bp
1. Operating Revenue and Operating Gain for Carelon for the three months ended March 31, 2023 included $8,024 and $512 for CarelonRx; $3,312
and $209 for Carelon Services, respectively. Operating Revenue and Operating Gain for Carelon for the three months ended March 31, 2022
included $6,683 and $398 for CarelonRx; $2,948 and $200 for Carelon Services, respectively.
2. See “Basis of Presentation” on page 5 herein.
3. "NM" = calculation not meaningful.
Health Benefits: Operating gain in the Health Benefits segment totaled $2,159 million in the first
quarter of 2023, an increase of $308 million from $1,851 million in the first quarter of 2022. The
increase was primarily driven by premium rate adjustments to more accurately reflect our post-pandemic
cost structure and membership growth in Medicaid.
Carelon: Operating gain in the Carelon segment was $721 million in the first quarter of 2023, an
increase of $123 million from $598 million in the first quarter of 2022. The increase was primarily
driven by higher prescription volumes associated with growth in integrated medical and standalone
pharmacy customers, improved performance in our care delivery business, and the expansion of our
post-acute care business.
Corporate & Other: The Company reported an operating loss of $49 million in the Corporate & Other
segment for the first quarter of 2023, a decrease of $27 million from an operating loss of $22 million in
the first quarter of 2022, driven by an increase in unallocated corporate expenses.
4

-- 4 of 13 --

Basis of Presentation
1. Operating revenue and operating gain/loss are the key measures used by management to evaluate
performance in each of its reporting segments, allocate resources, set incentive compensation
targets and to forecast future operating performance. Operating gain/loss is calculated as total
operating revenue less benefit expense, cost of products sold and operating expense. It does not
include net investment income, net gains/losses on financial instruments, interest expense,
amortization of other intangible assets, gains/losses on extinguishment of debt or income taxes, as
these items are managed in a corporate shared service environment and are not the responsibility of
operating segment management. Refer to page 12 for the GAAP reconciliation tables.
2. Operating margin is defined as operating gain divided by operating revenue.
Conference Call and Webcast
Management will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time (“EDT”)
to discuss the company’s first quarter results and outlook. The conference call should be accessed at
least 15 minutes prior to the start of the call with the following numbers:
888-947-9963 (Domestic) 866-361-4942 (Domestic Replay)
312-470-0178 (International) 203-369-0190 (International Replay)
The access code for today's conference call is 3972058. There is no access code for the replay. The
replay will be available from 11:30 a.m. EDT today, until the end of the day on May 19, 2023. The call
will also be available through a live webcast at www.elevancehealth.com under the “Investors” link. A
webcast replay will be available following the call.
Elevance Health Contacts:
Investor Relations Media
Stephen Tanal Leslie Porras
Stephen.Tanal@elevancehealth.com Leslie.Porras@elevancehealth.com
5

-- 5 of 13 --

About Elevance Health, Inc.
Elevance Health is a lifetime, trusted health partner fueled by its purpose to improve the health of
humanity. The company supports consumers, families, and communities across the entire care journey –
connecting them to the care, support, and resources they need to lead healthier lives. Elevance Health’s
companies serve more than 118 million people through a diverse portfolio of industry-leading medical,
digital, pharmacy, behavioral, clinical, and complex care solutions. For more information, please visit
www.elevancehealth.com or follow us @ElevanceHealth on Twitter and Elevance Health on LinkedIn.
6

-- 6 of 13 --

Elevance Health, Inc.
Membership and Other Metrics
(Unaudited)
Change from
Medical Membership (in thousands)
March 31,
2023 March 31,
2022 December 31,
2022 March 31,
2022 December 31,
2022
Individual 942 818 789 15.2 % 19.4 %
Employer Group Risk-Based 3,798 4,028 3,988 (5.7) % (4.8) %
Commercial Risk-Based 4,740 4,846 4,777 (2.2) % (0.8) %
BlueCard® 6,607 6,370 6,462 3.7 % 2.2 %
Employer Group Fee-Based 20,278 20,148 20,174 0.6 % 0.5 %
Commercial Fee-Based 26,885 26,518 26,636 1.4 % 0.9 %
Medicare Advantage 2,053 1,921 1,977 6.9 % 3.8 %
Medicare Supplement 925 939 947 (1.5) % (2.3) %
Total Medicare 2,978 2,860 2,924 4.1 % 1.8 %
Medicaid 11,889 10,919 11,571 8.9 % 2.7 %
Federal Employees Health Benefits 1,632 1,632 1,623 — % 0.6 %
Total Medical Membership 48,124 46,775 47,531 2.9 % 1.2 %
Other Membership (in thousands)
Life and Disability Members 4,771 4,679 4,834 2.0 % (1.3) %
Dental Members 6,743 6,649 6,692 1.4 % 0.8 %
Dental Administration Members 1,697 1,588 1,586 6.9 % 7.0 %
Vision Members 9,904 9,211 9,813 7.5 % 0.9 %
Medicare Part D Standalone Members 264 279 271 (5.4) % (2.6) %
Other Metrics (in millions)
CarelonRx Quarterly Adjusted Scripts 75.7 73.0 82.0 3.7 % (7.7) %
Carelon Services Consumers Served 104.0 104.0 105.0 — % (1.0) %
7

-- 7 of 13 --

Elevance Health, Inc.
Consolidated Statements of Income
(Unaudited)
(In millions, except per share data) Three Months Ended
March 31
2023 2022 Change
(Restated)
Revenues
Premiums $ 35,868 $ 32,785 9.4 %
Product revenue 4,022 3,301 21.8 %
Service fees 2,008 1,800 11.6 %
Total operating revenue 41,898 37,886 10.6 %
Net investment income 387 360 7.5 %
Net losses on financial instruments (113) (151) NM
Total revenues 42,172 38,095 10.7 %
Expenses
Benefit expense 30,786 28,231 9.1 %
Cost of products sold 3,481 2,883 20.7 %
Operating expense 4,800 4,345 10.5 %
Interest expense 251 201 24.9 %
Amortization of other intangible assets 235 129 82.2 %
Total expenses 39,553 35,789 10.5 %
Income before income tax expense 2,619 2,306 13.6 %
Income tax expense 615 527 16.7 %
Net income 2,004 1,779 12.6 %
Net (income) loss attributable to noncontrolling interests (15) 10 NM
Shareholders' net income $ 1,989 $ 1,789 11.2 %
Shareholders' net income per diluted share $ 8.30 $ 7.32 13.4 %
Diluted shares 239.7 244.4 (1.9) %
Benefit expense as a percentage of premiums 85.8 % 86.1 % (30) bp
Operating expense as a percentage of total operating revenue 11.5 % 11.5 % — bp
Income before income tax expense as a percentage of total revenue 6.2 % 6.1 % 10 bp
"NM" = calculation not meaningful
8

-- 8 of 13 --

Elevance Health, Inc.
Consolidated Balance Sheets
(In millions) March 31,
2023 December 31,
2022
Assets (Unaudited) (Restated)
Current assets:
Cash and cash equivalents $ 10,142 $ 7,387
Fixed maturity securities 27,636 25,952
Equity securities 392 953
Premium receivables 8,246 7,083
Self-funded receivables 3,786 4,663
Other receivables 4,678 4,298
Other current assets 4,943 5,281
Total current assets 59,823 55,617
Long-term investments:
Fixed maturity securities 783 752
Other invested assets 5,971 5,685
Property and equipment, net 4,418 4,316
Goodwill 25,273 24,383
Other intangible assets 10,915 10,315
Other noncurrent assets 1,857 1,687
Total assets $ 109,040 $ 102,755
Liabilities and equity
Liabilities
Current liabilities:
Medical claims payable $ 15,728 $ 15,596
Other policyholder liabilities 6,098 5,933
Unearned income 4,394 1,112
Accounts payable and accrued expenses 4,873 5,607
Short-term borrowings 265 265
Current portion of long-term debt — 1,500
Other current liabilities 10,531 9,683
Total current liabilities 41,889 39,696
Long-term debt, less current portion 25,201 22,349
Reserves for future policy benefits 811 803
Deferred tax liabilities, net 2,029 2,015
Other noncurrent liabilities 1,650 1,562
Total liabilities 71,580 66,425
Shareholders’ equity
Common stock 2 2
Additional paid-in capital 8,697 9,084
Retained earnings 30,707 29,647
Accumulated other comprehensive loss (2,050) (2,490)
Total shareholders’ equity 37,356 36,243
Noncontrolling interests 104 87
Total equity 37,460 36,330
Total liabilities and equity $ 109,040 $ 102,755
9

-- 9 of 13 --

Elevance Health, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
(In millions) Three Months Ended March 31
2023 2022
(Restated)
Operating activities
Net income $2,004 $1,779
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses on financial instruments 113 151
Equity in net earnings of other invested assets 30 (153)
Depreciation and amortization 462 358
Deferred income taxes (255) (96)
Share-based compensation 61 50
Changes in operating assets and liabilities:
Receivables, net (29) (1,348)
Other invested assets (15) 7
Other assets (348) (350)
Policy liabilities 306 1,092
Unearned income 3,282 57
Accounts payable and other liabilities 18 428
Income taxes 839 568
Other, net 1 (2)
Net cash provided by operating activities 6,469 2,541
Investing activities
Purchases of investments (7,443) (5,050)
Proceeds from sale of investments 2,489 3,047
Maturities, calls and redemptions from investments 3,533 1,209
Changes in securities lending collateral 204 (441)
Purchases of subsidiaries, net of cash acquired (1,638) (61)
Purchases of property and equipment (301) (254)
Other, net (28) (28)
Net cash used in investing activities (3,184) (1,578)
Financing activities
Net proceeds from commercial paper borrowings 325 225
Net proceeds from (repayments of) long-term borrowings 666 (14)
Changes in securities lending payable (205) 441
Changes in bank overdrafts (291) 529
Repurchase and retirement of common stock (622) (545)
Cash dividends (351) (309)
Proceeds from issuance of common stock under employee stock plans 43 76
Taxes paid through withholding of common stock under employee stock plans (98) (86)
Other, net 2 5
Net cash (used in) provided by financing activities (531) 322
Effect of foreign exchange rates on cash and cash equivalents 1 (4)
Change in cash and cash equivalents 2,755 1,281
Cash and cash equivalents at beginning of period 7,387 4,880
Cash and cash equivalents at end of period $10,142 $6,161
10

-- 10 of 13 --

Elevance Health, Inc.
Reconciliation of Medical Claims Payable
Three Months Ended
March 31 Years Ended December 31
2023 2022 2022 2021 2020
(In millions) (Unaudited) (Unaudited)
Gross medical claims payable, beginning of period $ 15,348 $ 13,282 $ 13,282 $ 11,135 $ 8,647
Ceded medical claims payable, beginning of period (6) (21) (21) (46) (33)
Net medical claims payable, beginning of period 15,342 13,261 13,261 11,089 8,614
Business combinations and purchase adjustments — 3 133 420 339
Net incurred medical claims:
Current year 30,751 28,064 113,414 100,440 85,094
Prior years redundancies(1) (1,068) (933) (869) (1,703) (637)
Total net incurred medical claims 29,683 27,131 112,545 98,737 84,457
Net payments attributable to:
Current year medical claims 19,948 17,116 98,997 88,156 74,629
Prior years medical claims 9,593 8,826 11,600 8,829 7,692
Total net payments 29,541 25,942 110,597 96,985 82,321
Net medical claims payable, end of period 15,484 14,453 15,342 13,261 11,089
Ceded medical claims payable, end of period 7 17 6 21 46
Gross medical claims payable, end of period $ 15,491 $ 14,470 $ 15,348 $ 13,282 $ 11,135
Current year medical claims paid as a percentage of
current year net incurred medical claims 64.9 % 61.0 % 87.3 % 87.8 % 87.7 %
Prior year redundancies in the current year as a
percentage of prior year net medical claims
payable less prior year redundancies in the
current year 7.5 % 7.6 % 7.0 % 18.1 % 8.0 %
Prior year redundancies in the current year as a
percentage of prior year net incurred medical
claims 0.9 % 0.9 % 0.9 % 2.0 % 0.8 %
(1) Negative amounts reported for net incurred medical claims related to prior years result from claims being settled for
amounts less than originally estimated.
11

-- 11 of 13 --

Elevance Health, Inc.
GAAP Reconciliation
(Unaudited)
Elevance Health, Inc. has referenced “Adjusted Net Income” and “Adjusted Net Income Per Share,” which are non-GAAP measures, in this document. These non-GAAP
measures are not intended to be alternatives to any measure calculated in accordance with GAAP. In addition to these non-GAAP measures, references are made to the
measures “Operating Revenue” and “Operating Gain.” Each of these measures is provided to further aid investors in understanding and analyzing the company’s core operating
results and comparing Elevance Health, Inc.’s financial results. A reconciliation of Operating Revenue to Total Revenue is set forth in the Consolidated Statements of Income
herein. A reconciliation of the non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP, together with a reconciliation of reportable
segments operating gain to income before income tax expense, is reported below. Prior amounts may be grouped differently to conform to current presentation.
Three Months Ended
March 31
(In millions, except per share data) 2023 2022 Change
Shareholders' net income - As reported $ 1,989 $ 1,805 10.2 %
Impact of Accounting Standards Update 2018-12 Adoption — (16)
Shareholders' net income - Restated $ 1,989 $ 1,789 11.2 %
Add / (Subtract):
Net losses on financial instruments 113 151
Amortization of other intangible assets 235 129
Transaction and integration related costs 26 9
Litigation expenses 1 1
Tax impact of non-GAAP adjustments (97) (78)
Net adjustment items 278 212
Adjusted shareholders' net income $ 2,267 $ 2,001 13.3 %
Shareholders' net income per diluted share - As reported $ 8.30 $ 7.39 12.3 %
Impact of Accounting Standards Update 2018-12 Adoption — (0.07)
Shareholders' net income per diluted share - Restated 8.30 7.32 13.4 %
Add / (Subtract):
Net losses on financial instruments 0.47 0.62
Amortization of other intangible assets 0.98 0.53
Transaction and integration related costs 0.11 0.04
Litigation expenses — —
Tax impact of non-GAAP adjustments (0.40) (0.32)
Net adjustment items 1.16 0.87
Adjusted shareholders' net income per diluted share $ 9.46 $ 8.19 15.5 %
Full Year 2023 Outlook
Shareholders' net income per diluted share Greater than $29.50
Add / (Subtract):
Net losses on financial instruments $0.47
Transaction and integration related costs $0.11
Amortization of other intangible assets $3.63
Tax impact of non-GAAP adjustments Approximately $(1.01)
Net adjustment items $3.20
Adjusted shareholders' net income per diluted share Greater Than $32.70
Three Months Ended
March 31
(In millions) 2023 2022 Change
(Restated)
Income before income tax expense $ 2,619 $ 2,306 13.6 %
Net investment income (387) (360)
Net losses on financial instruments 113 151
Interest expense 251 201
Amortization of other intangible assets 235 129
Reportable segments operating gain $ 2,831 $ 2,427 16.6 %
12

-- 12 of 13 --

Forward-Looking Statements
This document contains certain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial
performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,”
“should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are
intended to identify forward-looking statements. These statements include, but are not limited to: financial
projections and estimates and their underlying assumptions; statements regarding plans, objectives and
expectations with respect to future operations, products and services; and statements regarding future
performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict
and generally beyond our control, that could cause actual results to differ materially from those expressed in, or
implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these
forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and
consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and
Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our
business. Except to the extent required by law, we do not undertake to update or revise any forward-looking
statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties
include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to
secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public
health epidemics and pandemics, including COVID-19, and other catastrophes; the impact of new or changes in
existing federal, state and international laws or regulations, including healthcare laws and regulations, or their
enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or breaches or
our failure to comply with any privacy or security laws or regulations, including any investigations, claims or
litigation related thereto; information technology disruptions; changes in economic and market conditions, as
well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and
our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks
and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with
the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for
Medicare and Medicaid Services Star ratings and other quality scores and funding risks with respect to revenue
received from participation therein; a negative change in our healthcare product mix; costs and other liabilities
associated with litigation, government investigations, audits or reviews; our ability to contract with providers on
cost-effective and competitive terms; failure to effectively maintain and modernize our information systems; risks
associated with providing pharmacy, healthcare and other diversified products and services, including medical
malpractice or professional liability claims and non-compliance by any party with the pharmacy services
agreement between us and CaremarkPCS Health, L.L.C.; risks associated with mergers, acquisitions, joint
ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not
adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from
our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our
common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and
other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and
the risk that increased interest rates or market volatility could impact our access to or further increase the cost of
financing; a downgrade in our financial strength ratings; the effects of any negative publicity related to the health
benefits industry in general or us in particular; events that may negatively affect our licenses with the Blue Cross
and Blue Shield Association; intense competition to attract and retain employees; risks associated with our
international operations; and various laws and provisions in our governing documents that may prevent or
discourage takeovers and business combinations.
13

-- 13 of 13 --